|
||||||
Dermatology Facts—Squaric Acid DibutylesterHome Immunotherapy of Common Warts—ProtocolBenefits: 58% to 84% of patients clear their warts in three months. Partial clearing occurred in 10% to 18% of patients. Safety: Is non-toxic, non-mutagenic and easy to use. Risks: Possible mild to severe allergic reaction to SADBE (resembling poison oak). This is managed with a topical cortisone cream. Blistering and hypopigmentation (lightening of the skin) may occur. Cost: To the patient, approximately $45 to $110 depending on size. Cost may vary depending on the compounding pharmacy. Sensitization: 3% SABDE will be applied to a dime-sized area of the upper arm by the doctor or nurse. At this site, in the following one to two weeks, redness may develop in 10% of patients. A small amount of topical steroid will be given to treat this. Starting therapy:
Note: If you develop rash during therapy with SADBE, discontinue therapy and call our office. What to expect: Responders can expect improvements as early as one month, and clearance as early as three months. No change will generally be seen for the first 4 weeks of therapy. If nothing happens, do not stop the medication because you do not think it is working. Just be patient. Modifying therapy: If no response is seen at six weeks, the concentration of SABDE may be increased Made by: Squaric acid dibutylester: Made by Spectrum Chemicals Co., Gardena, CA. Compounding pharmacies:
|
||||||